Momenta Pharmaceuticals, Inc. (MNTA) CFO Scott M. Storer Sells 3,972 Shares

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) CFO Scott M. Storer sold 3,972 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Wednesday, February 14th. The shares were sold at an average price of $15.16, for a total transaction of $60,215.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) traded up $0.25 during trading hours on Wednesday, reaching $16.25. 934,334 shares of the company were exchanged, compared to its average volume of 927,339. The company has a market capitalization of $1,240.00, a PE ratio of -20.31 and a beta of 1.80. Momenta Pharmaceuticals, Inc. has a fifty-two week low of $11.85 and a fifty-two week high of $19.46.

MNTA has been the subject of a number of analyst reports. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. BidaskClub downgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Cowen set a $15.00 price target on shares of Momenta Pharmaceuticals and gave the company a “hold” rating in a research report on Wednesday, November 1st. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $18.00 price target on shares of Momenta Pharmaceuticals in a research report on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and one has given a buy rating to the company. Momenta Pharmaceuticals presently has an average rating of “Hold” and an average target price of $15.30.

A number of large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. increased its stake in Momenta Pharmaceuticals by 14.9% in the second quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 834 shares during the last quarter. California State Teachers Retirement System increased its stake in Momenta Pharmaceuticals by 1.6% in the second quarter. California State Teachers Retirement System now owns 130,075 shares of the biotechnology company’s stock valued at $2,198,000 after acquiring an additional 2,099 shares during the last quarter. California Public Employees Retirement System increased its stake in Momenta Pharmaceuticals by 2.2% in the second quarter. California Public Employees Retirement System now owns 133,200 shares of the biotechnology company’s stock valued at $2,251,000 after acquiring an additional 2,900 shares during the last quarter. LS Investment Advisors LLC increased its stake in Momenta Pharmaceuticals by 59.8% in the fourth quarter. LS Investment Advisors LLC now owns 9,300 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 3,479 shares during the last quarter. Finally, New York State Teachers Retirement System increased its stake in Momenta Pharmaceuticals by 4.3% in the third quarter. New York State Teachers Retirement System now owns 97,875 shares of the biotechnology company’s stock valued at $1,811,000 after acquiring an additional 4,000 shares during the last quarter. 93.01% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Momenta Pharmaceuticals, Inc. (MNTA) CFO Scott M. Storer Sells 3,972 Shares” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/14/momenta-pharmaceuticals-inc-mnta-cfo-scott-m-storer-sells-3972-shares.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply